Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

[1]  S. Krajewski,et al.  Down-regulation of Epidermal Growth Factor Receptor by Selective Expansion of a 5′-End Regulatory Dinucleotide Repeat in Colon Cancer with Microsatellite Instability , 2009, Clinical Cancer Research.

[2]  D. Sargent,et al.  Clinical implications of microsatellite instability in sporadic colon cancers , 2009, Current opinion in oncology.

[3]  D. Yip,et al.  Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH , 2009, Pathology.

[4]  G Milano,et al.  Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  E. Shpall,et al.  Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jin-Hwang Liu,et al.  Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma , 2007, Clinical Cancer Research.

[7]  G. Pond,et al.  Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Sargent,et al.  Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability , 2007, International journal of cancer.

[10]  R. Eisenberg,et al.  Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. , 2007, Lung cancer.

[11]  C. Ceccarelli,et al.  Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa , 2006, British Journal of Cancer.

[12]  D. Sargent,et al.  Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. , 2006, Gastroenterology.

[13]  D. Sargent,et al.  Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. , 2006, Clinical colorectal cancer.

[14]  D. Sargent,et al.  Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability , 2006, Clinical Cancer Research.

[15]  S. Kim-Schulze,et al.  Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Harris,et al.  Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. , 2006, Cancer research.

[17]  D. Larsimont,et al.  Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. , 2005, Seminars in oncology.

[18]  W. Gerald,et al.  Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study , 2005, Modern Pathology.

[19]  H. Modjtahedi,et al.  Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. , 2005, International journal of oncology.

[20]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  F. Penault-Llorca,et al.  Impact of EGFR expression on colorectal cancer patient prognosis and survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  D. Sargent,et al.  Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Baselga,et al.  Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) , 2004, Clinical Cancer Research.

[24]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[25]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[26]  E. Sabo,et al.  Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer , 2004, Clinical Cancer Research.

[27]  E. Sabo,et al.  Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  M. Hayman,et al.  Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor Signaling , 2003, Molecular and Cellular Biology.

[29]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[30]  G. Tortora,et al.  Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. , 2003, European journal of cancer.

[31]  A. Flahault,et al.  Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression , 2003, Virchows Archiv.

[32]  H. McLeod,et al.  Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. , 2002, European journal of cancer.

[33]  J. C. Lee,et al.  Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. , 2002, European journal of cancer.

[34]  D. Sargent,et al.  Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. Kay Washington,et al.  Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[38]  J. McKay,et al.  Cyclin D1 protein expression and gene polymorphism in colorectal cancer , 2000, International journal of cancer.

[39]  S. Thibodeau,et al.  HMSH6 alterations in patients with microsatellite instability-low colorectal cancer. , 2000, Cancer research.

[40]  Carolyn Compton,et al.  American Joint Committee on Cancer prognostic factors consensus conference , 2000, Cancer.

[41]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[42]  G. Carpenter,et al.  The Role of Individual SH2 Domains in Mediating Association of Phospholipase C-γ1 with the Activated EGF Receptor* , 1999, The Journal of Biological Chemistry.

[43]  D. Schaid,et al.  Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. , 1999, Journal of the National Cancer Institute.

[44]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[45]  D. Schaid,et al.  Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. , 1998, Cancer research.

[46]  H. Hibshoosh,et al.  Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. , 1996, Gastroenterology.

[47]  D. Kassel,et al.  In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-src: identification of phosphorylation sites and c-src SH2 domain binding sites. , 1995, Biochemistry.

[48]  T. Koji,et al.  Expression of epidermal growth factor receptor messenger RNA in human colorectal carcinomas assessed by non-radioactive in-situ hybridization. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[49]  C. Bucana,et al.  Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[51]  Y. Kido,et al.  Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. , 1994, The Journal of biological chemistry.

[52]  L. Aaltonen,et al.  Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. , 1993, Cancer research.

[53]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[54]  D.,et al.  Regression Models and Life-Tables , 2022 .